Format

Send to

Choose Destination
Leukemia. 2004 Feb;18(2):219-26.

Interleukin-3 receptor in acute leukemia.

Author information

1
Department of Hematology and Oncology, Istituto Superiore di Sanità, Viale Regina Elena 299, Rome, Italy. u.testa@iss.it

Abstract

Recent studies indicate that abnormalities of the interleukin-3 receptor (IL-3R) are frequently observed in acute myeloid leukemias (AMLs) and may contribute to the proliferative advantage of leukemic blasts. This review analyzes the evidences indicating that the IL-3R represents one of the target molecules involved in the stimulation of proliferation of AMLs, and the overexpression of the IL-3Ralpha chain may represent one of the mechanisms contributing to the development of a highly malignant leukemic phenotype. Furthermore, there is evidence that the IL-3Ralpha is a marker of leukemic stem cells, at variance with normal stem cells that are IL-3Ralpha-. Finally, the IL-3R may represent an important target for the development of new antileukemic drugs.

PMID:
14671644
DOI:
10.1038/sj.leu.2403224
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center